RxDoctor Payments Data

Michael Berte, MD

Urology · Cleveland, OHNPI 1013985316

Payments from drug & device makers

$12,465in general payments, 2019–2025

Across 612 payments — averaging $20.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Procept Biorobotics Corporation$1K
  • Astellas Pharma US Inc$1K
  • Antares Pharma, Inc.$742
  • Blue Earth Diagnostics$678
  • Dendreon Pharmaceuticals LLC$585
  • Neotract Inc.$568
  • plus $7K from 47 others

What the payments were for

  • Travel & lodging$8197%
  • Food & beverage$11,35291%
  • Education$2942%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,465 in reported general payments places this provider in the 80th percentile of 485 urology providers in Ohio.

See all urology providers in Ohio

Medicare billing

Part B allowed, 2024
$136,168
Medicare patients
576
Services billed
4,080

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron137$112,074
GemtesaVibegron45$29,385
Mirabegron ErMirabegron13$12,489
Tamsulosin Hcl826$10,812
Finasteride679$8,319
Potassium Citrate ErPotassium Citrate43$3,560
Solifenacin Succinate67$2,862
Alfuzosin Hcl ErAlfuzosin Hcl90$2,627
Testosterone19$2,273
Oxybutynin Chloride ErOxybutynin Chloride65$1,961
Tolterodine Tartrate ErTolterodine Tartrate15$1,402
Oxybutynin Chloride80$1,352
NitrofurantoinNitrofurantoin Macrocrystal72$1,299
Doxazosin Mesylate56$1,192
Estradiol12$700

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$1,210$112,074137 claims
Sumitomo Pharma America, Inc.Gemtesa$319$29,38545 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 485 urology providers in Ohio.

Other urology in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →